For this peptide source, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last March, a guy named Rob in Scottsdale told me something that stuck. Rob is 47, a commercial real estate broker who’d been on TRT for three years and still felt like his recovery and body composition had stalled. His prescriber added CJC-1295 (no-DAC) and ipamorelin to his protocol. Eight months later, Rob’s DEXA showed he’d dropped from 24.1 to 20.3 percent body fat without changing his training. “I kept waiting for the other shoe to drop,” he said. “Some weird side effect, or for it to stop working. It just… kept being boring and effective.” That phrase, boring and effective, is maybe the best two-word summary of this stack that exists.
There’s a reason nearly every prescriber writing peptide protocols lands on some version of CJC-1295 plus ipamorelin. The two peptides hit different receptors in the GH axis, and when combined, the effects compound. Not in theory. In practice. It’s the most-prescribed combination in compounded peptide therapy for adult growth hormone support, and it’s been that way for years now.
I’ve been running variations of this stack for 14 months. What follows is the full breakdown: how the pharmacology works, how I dose it, what I’ve actually measured, and the practical decisions I screwed up or got right along the way.
The compliance part you can’t skip: Both CJC-1295 (DAC and no-DAC forms) and ipamorelin are not FDA-approved for any human indication. In the United States, they’re accessed through compounding pathways, prepared by licensed 503A pharmacies for individual patient prescriptions based on a physician’s clinical judgment. The FDA placed both peptides on the 503A bulks list under review in 2023. None of this is medical advice.
The Receptor Logic Behind the Combination
CJC-1295 is a growth hormone releasing hormone (GHRH) analog. It binds the GHRH receptor on pituitary somatotrophs and tells them to release GH.
Ipamorelin is a selective growth hormone secretagogue. It binds the ghrelin receptor (GHS-R1a) and also triggers GH release, but through a completely separate mechanism.
Here’s the thing: both receptor types sit on the same pituitary cells, but they activate different intracellular signaling cascades. Stimulate both simultaneously and you get a GH pulse larger than either peptide produces alone. Published animal data and the limited human data both confirm this additive (possibly synergistic) effect. The resulting pulse also more closely resembles the amplitude of natural GH pulses in younger adults.
Think of it like pushing a car that’s already rolling downhill. One push gets it moving. Two pushes from different angles get it moving faster and straighter. That’s the receptor biology behind the “gold standard” label. Not marketing copy. Actual pharmacology.
DAC or No-DAC: A Choice That Matters More Than You Think
CJC-1295 comes in two forms, and the difference between them is not trivial.
CJC-1295 with DAC (drug affinity complex) binds to albumin in the bloodstream and hangs around for 6 to 8 days. One weekly dose creates a sustained, near-constant GH-releasing signal. Some clinicians call this the “GH bleed” because it flattens the pulsatile rhythm into something closer to a continuous hum.
CJC-1295 without DAC clears in about 30 minutes. Each injection briefly amplifies the natural GH pulse, then it’s gone. You need to dose it daily (or close to it), typically paired with ipamorelin at a consistent time.
The choice between them is strategic, not cosmetic. DAC is more convenient and tends to produce higher average IGF-1 levels. No-DAC preserves more of the natural pulsatile rhythm, which many prescribers believe is healthier long-term.
I started on DAC because I liked the idea of two shots a week on top of nightly ipamorelin. Simple. My IGF-1 climbed quickly to 232, which my prescriber flagged as approaching the upper end of where he wanted me. At week 6, I had a mild fluid retention episode (rings tight, ankles slightly puffy) that resolved within days after a dose reduction. Six months in, we ditched DAC entirely and switched to no-DAC at 100 mcg alongside the nightly ipamorelin shot. IGF-1 settled into a 180 to 195 range and stayed there.
My prescriber’s default recommendation for general anti-aging or body composition support is no-DAC. He reserves DAC for specific clinical situations. After living on both sides, I agree with him.
The Protocol I Actually Run
- 100 mcg CJC-1295 (no-DAC) plus 200 mcg ipamorelin, combined subcutaneous in the same syringe
- 5 nights a week, 60 to 90 minutes before sleep, on an empty stomach
- Injection site: rotating four abdominal quadrants
- 8 weeks on, 2 weeks off, ongoing for 14 months
The peptides are compatible in the same syringe in solution. Total injection volume is tiny, under 0.2 mL at my concentrations. The whole ritual takes maybe 90 seconds.
Fourteen Months of Data (and What’s Subjective vs. What’s Not)
Sleep. This is the effect people notice first, and it’s real. My Oura sleep score has averaged 83 over the past 12 weeks, up from a pre-protocol average of 75. Deep sleep minutes are up roughly 22 percent. I sleep like someone unplugged me.
Body composition. DEXA at baseline: 22.4 percent body fat. DEXA at 12 months: 18.9 percent. Lean mass essentially preserved. No dramatic intervention to explain this. My cardio frequency, training volume, and protein intake were constant throughout. The change accumulated slowly, which is exactly what you’d expect from a modest but persistent GH optimization.
IGF-1. Baseline 128. Treatment range 180 to 195. No upward drift over time at a stable dose, which is worth noting because runaway IGF-1 is the concern that keeps prescribers up at night.
Skin and connective tissue. Subjective only, and I’ll be honest about that. The skin on my forearms and hands looks less dry, less crepey. My partner noticed this at month 8, before I did. There’s no way to measure it objectively, so take it for what it is.
Recovery. The most reliable subjective benefit. Soreness clears faster between training sessions. Heavy leg day on Monday no longer means I’m shuffling around like I aged a decade on Tuesday. This one alone keeps me on the protocol.
Hair and nails. Nothing. No change either direction.
Side Effects: Short List
The fluid retention on DAC was the only meaningful side effect. It resolved with dose adjustment and didn’t recur after switching to no-DAC.
Some mild flushing during the first two weeks of treatment, lasting under a minute per injection. Gone by week three.
No appetite spike, which surprised me. Ipamorelin hits the ghrelin receptor, and some users report increased hunger. I never experienced it, possibly because I dose at night and I’ve been at maintenance calories throughout. Your mileage may genuinely vary on this one.
No glucose disruption. Fasting glucose has stayed in the 87 to 93 range the entire time. A1C went from 5.4 to 5.2.
Three Things I’d Do Differently
Skip DAC from the start. The convenience of twice-weekly dosing wasn’t worth the elevated IGF-1 trajectory or the fluid retention scare. No-DAC is more work, but the response curve has been cleaner and more predictable.
Get a baseline DEXA on day one. I relied on calipers and a scale for the first six months. The DEXA at month 6 was the moment the body composition story became real and quantifiable. I wish I had that data point at month zero.
Set up the prescriber relationship first. I had my peptides before I had my doctor properly involved, which is backwards. Having a real physician running labs and adjusting doses is the part that makes this medicine instead of guesswork. Don’t do it the other way around.
Where I Source and What It Costs
I source through this peptide source, a compounded telehealth pharmacy working with licensed 503A compounding pharmacies that fulfills prescriptions written by my physician. The lots come labeled with beyond-use dating, lot numbers, and a sterility statement available on request. Cost runs about $185 a month for the combined stack at my doses, plus quarterly labs through my doctor’s office.
Other 503A pharmacies do this work too. The pharmacy quality, labeling discipline, and traceability matter far more than whatever brand name is on the front of the website.
Where This Falls Apart (or Just Falls Short)
This stack will not make you 25 again. The magnitude of effect on body composition and recovery is real but moderate. It will not let you skip training, sleep, or adequate protein. Those are the actual drivers. The peptides amplify what the basics give you. Without the basics, there’s nothing to amplify.
It will not produce noticeable results in week one. The arc is months, not weeks. Six months is the minimum evaluation window. Twelve months is when you can truly see the trajectory and decide if it’s worth continuing.
And it’s not a forever protocol without periodic reassessment. I’m taking my third extended break in October. The point is to use it as a tool with defined on/off periods, not as a permanent fixture.
Fourteen months in, the boring truth is that this stack has lived up to its reputation. Not spectacularly. Not with fireworks. Just quietly, consistently, backed by labs that keep coming back where they should be.
Not FDA-approved. Compounded CJC-1295 and ipamorelin are prescribed and dispensed by licensed pharmacies for individual patient prescriptions based on clinical judgment. This is not medical advice.
Frequently Asked Questions
What is the standard dosing range for the CJC-1295/ipamorelin stack? Most prescribers work within 100 to 300 mcg of CJC-1295 (no-DAC) combined with 100 to 300 mcg of ipamorelin per injection, administered subcutaneously before bed. Dosing is individualized based on labs and clinical response.
How quickly will I notice results? Sleep quality improvements tend to show up within the first two to four weeks. Body composition changes are slower, typically becoming measurable by month three to six. Recovery benefits fall somewhere in between.
Is the CJC-1295/ipamorelin combination safe long-term? Long-term safety data in humans is limited because these peptides have not gone through full FDA approval trials. The existing clinical and compounding experience is encouraging, but periodic lab monitoring (IGF-1, fasting glucose, A1C) is non-negotiable. Work with a prescriber who actually watches your bloodwork.
Do I need to cycle off? Most prescribers recommend cycling, typically 8 weeks on and 2 to 4 weeks off. The rationale is to prevent receptor desensitization and to periodically verify that your own GH axis still functions normally without pharmacological support.
Can I combine this stack with other peptides like BPC-157 or thymosin beta-4? Many practitioners do layer additional peptides, but each addition increases complexity and the potential for interactions. This should only be done under direct clinical supervision with appropriate lab monitoring.
Does food timing matter? Yes. Fat and carbohydrate intake within 60 to 90 minutes of injection can blunt the GH pulse. Dosing on an empty stomach, ideally before bed after your last meal has cleared, is the standard recommendation.
Will this stack show up on a drug test? Peptide testing is uncommon in standard workplace drug panels but is increasingly included in athletic anti-doping protocols. If you’re subject to WADA, USADA, or similar testing, both CJC-1295 and ipamorelin are prohibited substances.
